SCHEMBL2962697

SCHEMBL2962697

COC(=O)CCn1ccnc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 3/20 0.52
POLB P06746 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 1/20 0.43
FDPS P14324 1/20 0.43
ESR1 P03372 1/20 0.42
ALPL P05186 2/20 0.41
ALPG P10696 2/20 0.41
ALPI P09923 1/20 0.41
PLAA Q9Y263 1/20 0.41
GFER P55789 1/20 0.40
HPGD P15428 1/20 0.40
KAT2B Q92831 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970107 0.85 ALDH1A1 (0.53) KMT2AALDH1A1POLBCA12CA1
SCHEMBL2960305 0.83 ALPL (0.50) KMT2AALDH1A1POLBSMN1; SMN2KDM4E
SCHEMBL2633151 0.83 KMT2A (0.50) KMT2AALDH1A1POLBCA12CA1
SCHEMBL16093158 0.82 KMT2A (0.44) KMT2AALDH1A1POLBCA12CA1
SCHEMBL16364921 0.82 TLR8 (0.50) KMT2AALDH1A1SMN1; SMN2HTTTSHR
SCHEMBL9726075 0.82 SMN1; SMN2 (0.41) KMT2AALDH1A1SMN1; SMN2HTTTSHR
SCHEMBL5707866 0.81 KMT2A (0.49) KMT2AALDH1A1POLBCA12CA1
SCHEMBL18510088 0.81 ALDH1A1 (0.49) KMT2AALDH1A1POLBCA12CA1
SCHEMBL17916298 0.81 ALDH1A1 (0.49) KMT2AALDH1A1POLBCA12CA1
SCHEMBL992745 0.81 SMN1; SMN2 (0.61) KMT2AALDH1A1POLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183616-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-09-28 WO disclosed
EP-3037452-B1 ONE-PART CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2019-04-10 EP disclosed
US-9757944-B2 Liquid jet head and method for producing same, and liquid jet apparatus and image forming apparatus RICOH COMPANY, LTD. (JP) 2017-09-12 US disclosed
US-20170043580-A1 LIQUID JET HEAD AND METHOD FOR PRODUCING SAME, AND LIQUID JET APPARATUS AND IMAGE FORMING APPARATUS RICOH COMPANY, LTD. (JP) 2017-02-16 US disclosed
CN-103980204-B Ionic liquid-catalyzed amine and α, β-unsaturated electron deficiency receptor method TAIZHOU UNIVERSITY (CN) 2016-03-30 CN disclosed
CN-103980204-A Method for catalyzing amines and alpha, beta-unsaturated electron-deficient acceptors by ionic liquid UNIV TAIZHOU 2014-08-13 CN disclosed
US-7763728-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-07-27 US disclosed
US-7714136-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-05-11 US disclosed
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 US disclosed
US-20090257977-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES PEKARI KLAUS 2009-10-15 US disclosed
US-20080260749-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-10-23 US disclosed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 US disclosed
EP-1896484-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-12 EP disclosed
EP-1893618-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-05 EP disclosed
WO-2006125815-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO disclosed
WO-2006125813-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257977-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES BAX, BCL2, CCAR2 KMT2A 2418/4885ALDH1A1 632/4885POLB 2460/4885
US-20080260749-A1 Novel Tetrahydropyridothiophenes BAX, BCL2, CCAR2 KMT2A 2644/4885ALDH1A1 615/4885POLB 2674/4885
US-20080206258-A1 Novel Tetrahydropyridothiophenes BAX, BCL2, CCAR2 KMT2A 2644/4885ALDH1A1 615/4885POLB 2674/4885
US-20090258873-A1 Novel tetrahydropyridothiophenes BAX, BCL2, CCAR2 KMT2A 2418/4885ALDH1A1 632/4885POLB 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.